Barclays PLC assumed coverage on shares of Myovant Sciences Ltd (NASDAQ:MYOV) in a report released on Monday. The firm set an “overweight” rating on the stock.

Separately, Robert W. Baird began coverage on shares of Myovant Sciences in a research note on Monday. They set an “outperform” rating and a $20.00 price target for the company.

Myovant Sciences (NASDAQ:MYOV) opened at 11.25 on Monday. The company’s market capitalization is $490.39 million. The stock has a 50 day moving average of $11.46 and a 200 day moving average of $11.46. Myovant Sciences has a 12 month low of $10.26 and a 12 month high of $13.31.

Myovant Sciences Company Profile

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.

5 Day Chart for NASDAQ:MYOV

Receive News & Stock Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related stocks with our FREE daily email newsletter.